Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C
Viruses · 2023
DOI: 10.3390/v15010181 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Naoki Kawagishi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Sapporo 0608638, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis C, Chronic, Hepatitis C. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Progressive liver fibrosis after anti-HCV treatment is a risk factor for HCC. Angiopoietin-2 (Ang2) is associated with non-regression of liver fibrosis after direct-acting antiviral (DAA). This study evaluated the predictive value of serum Ang2 levels for HCC occurrence or recurrence after DAA administration. In this retrospective study, 310 HCV-infected patients treated with DAAs in 2014–2020 were screened and evaluated for HCC occurrence or recurrence every three–six months. Multivariate Cox regression analysis revealed that age ≥ 75 years (HR: 2.92, 95% CI: 1.34–6.33; p = 0.007) and baseline Ang2 level ≥ 464 pg/mL (HR: 2.75, 95% CI: 1.18–6.37; p = 0.019) were significantly associated with HCC occurrence after DAA therapy. A high or low risk of HCC after DAA therapy could be distinguished by the combination of age and baseline Ang2 level. The cumulative incidences of de-novo HCC at two and four years were 0.8% and 3.8% in the low-risk group and 22.6% and 27.1% in the high-risk group, respectively. Baseline Ang2 level ≥ 402 pg/mL was significantly associated with HCC recurrence in patients who achieved sustained virological response with DAAs (HR: 3.68). In conclusion, serum Ang2 levels can predict HCC occurrence and recurrence after successful HCV eradication by DAAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Sapporo 0608638, Japan.
- Department of Gastroenterology, Hakodate Municipal Hospital, Sapporo 0608638, Japan.
- Department of Gastroenterology and Hepatology, Japan Community Health Care Organization (JCHO) Hokkaido Hospital, Sapporo 0608638, Japan.
- Laboratory of Molecular and Cellular Medicine, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo 0608638, Japan.
ORCID-Profile: Shunsuke Ohnishi, Masatsugu Ohara, Masato Nakai, Mitsuteru Natsuizaka
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Kawagishi, N., Suda, G., Yamamoto, Y., Baba, M., Furuya, K., Maehara, O., Ohnishi, S., Yoshida, S., Fu, Q., Yang, Z., Hosoda, S., Tokuchi, Y., Kitagataya, T., Ohara, M., Suzuki, K., Nakai, M., Sho, T., Natsuizaka, M., Ogawa, K., & Sakamoto, N. (2023). Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C. Viruses. https://doi.org/10.3390/v15010181
Vancouver
Kawagishi N, Suda G, Yamamoto Y, Baba M, Furuya K, Maehara O, et al. Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C. Viruses. 2023. doi:10.3390/v15010181
BibTeX
@article{Kawagishi2023,
author = {Kawagishi, Naoki and Suda, Goki and Yamamoto, Yoshiya and Baba, Masaru and Furuya, Ken and Maehara, Osamu and Ohnishi, Shunsuke and Yoshida, Sonoe and Fu, Qingjie and Yang, Zijian and Hosoda, Shunichi and Tokuchi, Yoshimasa and Kitagataya, Takashi and Ohara, Masatsugu and Suzuki, Kazuharu and Nakai, Masato and Sho, Takuya and Natsuizaka, Mitsuteru and Ogawa, Koji and Sakamoto, Naoya},
title = {Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15010181}
}
EUVIMED